Skip to Main Content (Press Enter)

Logo UNIBS
  • ×
  • Home
  • Persone
  • Strutture
  • Competenze
  • Pubblicazioni
  • Professioni
  • Corsi
  • Insegnamenti
  • Terza Missione

Competenze & Professionalità
Logo UNIBS

|

Competenze & Professionalità

unibs.it
  • ×
  • Home
  • Persone
  • Strutture
  • Competenze
  • Pubblicazioni
  • Professioni
  • Corsi
  • Insegnamenti
  • Terza Missione
  1. Pubblicazioni

Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry

Articolo
Data di Pubblicazione:
2024
Abstract:
Objectives Our primary objective was to quantify damage burden measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in aPL-positive patients with or without a history of thrombosis in an international cohort (the APS ACTION cohort). Secondly, we aimed to identify clinical and laboratory characteristics associated with damage in aPL-positive patients. Methods In this cross-sectional study, we analysed the baseline damage in aPL-positive patients with or without APS classification. We excluded patients with other autoimmune diseases. We analysed the demographic, clinical and laboratory characteristics based on two subgroups: (i) thrombotic APS patients with high vs low damage; and (ii) non-thrombotic aPL-positive patients with vs without damage. Results Of the 826 aPL-positive patients included in the registry as of April 2020, 586 with no other systemic autoimmune diseases were included in the analysis (412 thrombotic and 174 non-thrombotic). In the thrombotic group, hyperlipidaemia (odds ratio [OR] 1.82; 95% CI 1.05, 3.15; adjusted P = 0.032), obesity (OR 2.14; 95% CI 1.23, 3.71; adjusted P = 0.007), a & beta;(2)GPI high titres (OR 2.33; 95% CI 1.36, 4.02; adjusted P = 0.002) and corticosteroid use (ever) (OR 3.73; 95% CI 1.80, 7.75; adjusted P < 0.001) were independently associated with high damage at baseline. In the non-thrombotic group, hypertension (OR 4.55; 95% CI 1.82, 11.35; adjusted P = 0.001) and hyperlipidaemia (OR 4.32; 95% CI 1.37, 13.65; adjusted P = 0.013) were independent predictors of damage at baseline; conversely, single aPL positivity was inversely correlated with damage (OR 0.24; 95% CI 0.075, 0.77; adjusted P = 0.016). Conclusions DIAPS indicates substantial damage in aPL-positive patients in the APS ACTION cohort. Selected traditional cardiovascular risk factors, steroids use and specific aPL profiles may help to identify patients more prone to present with a higher damage burden.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
anti-beta-2 glycoprotein I antibodies; anticardiolipin; antiphospholipid antibodies; antiphospholipid syndrome; cardiovascular disease; damage; lupus anticoagulant; risk factors
Elenco autori:
Balbi, Gustavo G M; Ahmadzadeh, Yasaman; Tektonidou, Maria G; Pengo, Vittorio; Sciascia, Savino; Ugarte, Amaia; Belmont, H Michael; Lopez-Pedrera, Chary; Fortin, Paul R; Wahl, Denis; Gerosa, Maria; de Jesús, Guilherme R; Ji, Lanlan; Atsumi, Tatsuya; Efthymiou, Maria; Branch, D Ware; Nalli, Cecilia; Rodriguez Almaraz, Esther; Petri, Michelle; Cervera, Ricard; Knight, Jason S; Artim-Esen, Bahar; Willis, Rohan; Bertolaccini, Maria Laura; Cohen, Hannah; Roubey, Robert; Erkan, Doruk; de Andrade, Danieli Castro Oliveira
Link alla scheda completa:
https://iris.unibs.it/handle/11379/602745
Pubblicato in:
RHEUMATOLOGY
Journal
  • Assistenza
  • Privacy
  • Utilizzo dei cookie
  • Note legali

Realizzato con VIVO | Designed by Cineca | 26.5.1.0